- Home
- MVIS vs AURA Comparison
MVIS vs AURA Comparison
Compare MVIS & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVIS | AURA |
|---|---|---|
| Founded | 1993 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.0M | 396.8M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MVIS | AURA |
|---|---|---|
| Price | $0.89 | $5.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.50 | ★ $20.20 |
| AVG Volume (30 Days) | ★ 4.3M | 196.3K |
| Earning Date | 11-11-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,635,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $859.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.81 | $4.35 |
| 52 Week High | $1.95 | $8.27 |
Technical Indicators
Market Signals| Indicator | MVIS | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 35.98 |
| Support Level | $0.82 | $4.84 |
| Resistance Level | $0.98 | $5.30 |
| Average True Range (ATR) | 0.05 | 0.33 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 38.89 | 13.33 |
Price Performance
Historical ComparisonAbout MVIS MicroVision Inc.
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.